FDA's Companion Dx Guidance Slated for Early 2011; Codevelopment Guidance out Later, Gutierrez Says

Until now, the FDA has not publicly stated that it intends to issue two separate guidances on Rx/Dx development: one focusing solely on advancing companion tests, and another document on how to gain regulatory approval for a drug and test simultaneously.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.